In gynecological cancers, particularly OCs and ECs, the activation of the KRAS pathway and the presence of KRAS mutations are substantial factors contributing to both de novo and acquired resistance against PI3K pathway inhibitors [43] (Table 2). The gene discussed is PIK3CB; the disease is female reproductive organ cancer.